Quarterlies: A data dump of intrigue and a smidgen of smoke and mirrors. But while the pain is akin to meeting your boyfriend’s parents, it always reveals a hell of a lot about the boy, inside the man.

And so, Stockhead’s sublimely single but ever undaunted Edward ‘The Eagle-eye’ Sunarto has here given up several hours of his young life to plough through the glioblastomas, the transaction volumes and the recurring run rates to strip out the hyperbole and bring you a fine cross-selection of small cap quarterlies.

Bon appetit!


Prescient (ASX:PTX)

Prescient ended the quarter in a strong financial position, with a cash balance of $13.12 million as it looks to advance its cancer therapy programs.

During the quarter, the company made the decision to expand the PTX-100 trial on T-cell lymphomas, following excellent safety data and promising evidence of clinical efficiency. Recruitment is now open for the expanded cohort of the Phase 1b PTX-100 study.

Solid progress was also made on the OmniCAR platform during the quarter. Current pre-clinical work is focused on three programs: acute myeloid luekemia (AML), Her2 positive solid cancers and glioblastoma multiforme (GMB), an aggressive form of brain cancer.

Meanwhile, Prescient’s Cell Therapy Enhancements (CTE) program is an ongoing collaboration with the world- renowned Peter MacCallum Cancer Centre aimed at improving the current-generation of CAR-T treatments.

The company says the insights generated in the collab will be directly applicable to the next-generation CAR-T treatments Prescient is developing.

Registry Direct (ASX:RD1)

Registry Direct continued its positive growth trajectory, increasing receipts from customers to $267,000, up 22% on pcp.

Over the March quarter, Registry Direct added a net 28 new fee-paying registers to its business, continuing on the momentum from the previous quarters.

The company also continued to enhance its leading-edge registry technology platform.

Upgrades and improvements have been made, including that of Capital Call management, a new functionality developed to allows users to manage the capital call process from end to end, including the generation and sending of invoices, approval of payments, creation of capital call transactions and sending of receipts.

CHESS replacement project was also being progressed in the quarter to ensure that Registry Direct is ready, and on track for the ASX CHESS replacement project transition.

The company says it is well positioned to complete the ITE2 accreditation process once commenced by the ASX. This is an essential stage gate which all participants must meet to progress to the next phase of the project.

Wellnex Life (ASX:WNX)

Wellnex’s quarter builds on the strong performance of prior quarters, with growth recorded across the whole business and significant progress made in launching new products across shelves nationwide.

Cash receipts for the quarter were $3.6 million, up 606% compared to pcp. There was also an additional $2.1 million received in purchase orders for the liquid paracetamol product.

Net cash loss for the period was $840,000, compared to $2.95 million for the previous quarter (a decrease of 71%), with a majority of expenses being for the purchase of inventory of around $2.5 million.

To minimise supply chain issues, Wellnex has invested heavily in increasing its inventory holding to ensure continuity of supply.

During the quarter, Wellnex, in a joint venture with Australian Dairy Nutritionals, secured ranging in Chemist Warehouse for Australia’s first locally produced Organic A2 infant formula range, under the new brand Ocean Road Dairies.

Wakey Wakey and The Iron Company were also successfully ranged on shelves in leading grocery retailers, Coles and Woolworths.

Wellnex also signed a significant supply agreement with GlaxoSmithKline Consumer Trading Services, for the supply in Australia and New Zealand of its existing soft gel liquid analgesic for a minimum of 3 years.

Osteopore (ASX:OSX)

During the quarter, Osteopore delivered on revenue growth momentum, achieving S$371,929 (A$375,386) in revenue for Q1 CY22.

This represents a 21% growth on the last quarter, resulting in the second consecutive quarter of revenue growth, and delivering a 13.5% increase over the pcp.

The company also expanded into new distribution network and market access. Osteopore currently has a number of highly successful distributor agreements already in place across many major world markets, with further distribution agreements recently secured that enhance its global reach.

The first of these agreements saw the company expand its footprint to the Middle East, with the first shipment of its cranial regenerative implants to the United Arab Emirates (UAE). Osteopore will now aim to harness this opportunity and gain new regulatory access in additional Middle East territories.

Continuous improvements have been made to existing systems and processes, as well as leveraging on new technology to “sharpen the saw”.

In early March, Osteopore commenced a study in partnership with Singular Health Group (ASX: SHG) to improve the accuracy and workflow efficiency of Osteopore’s customised cranial implants.

The study is part of the company’s strategy to collaborate with a range of technologies to improve the efficacy of its regenerative implants and improve patient outcomes.

Gefen (ASX:GFN)

Gefen continues to accelerate growth in all key metrics during the quarter.

Cash receipts from customers were up 31% on the pcp to US$2.83 million, while the number of Arena agents using the Gefen Arena platform was up 89% on pcp to 2,522.

Meanwhile, the number of end customers using Gefen Arena platform was up 531% on pcp to 410,000.

During the quarter, Gefen also completed the onboarding of acquisition company Roeto, an Israeli company that provides a SaaS CRM platform for life insurers and financial planners.

Gefen’s transition to a transactional revenue model is now delivering very strong financial results, with significant growth across all of our key metrics.

The company provides a unique technology solution to highly regulated and compliance focused industries, that is fundamentally improving the way agents within the insurance and finance industries work.

Way2Vat (ASX:W2V)

For the first quarter, transaction volume were $2.23 million, up 62% on prior corresponding quarter (pcp). The company also grew the number of its small and medium-sized business (SMB) clients by 7% from 700 to 750 during the quarter.

In addition, W2V signed ten new multinational enterprise customers including Playmobil, a top-30 global toy manufacturer and enterprise headquartered in Germany, taking enterprise customer total to 210 – an increase of 40% in 12 months.

W2V also entered into various strategic partnerships during the quarter.

The first was with Circula, the largest expense management solution provider in Germany, to offer Circula clients use of Way2VAT’s automated VAT claim and return solutions product for SMBs through two integrated systems.

It also partnered with Railsbank and Mastercard, to launch world-first spending card automating VAT/GST returns for SMB and Enterprise market.

At quarter end, W2V’s cash receipts increased to $354k, up 45% from $243k in Q4 FY21. This resulted in a cash balance of $2.674 million as at 31 March.

Exopharm (ASX:EX1)

During the quarter, Exopharm has provided continued leadership within the exosome sector, with exosomes (also known as extracellular vesicles (EVs)) heralded as the ‘next big thing’ at the RNA Leaders World Congress.

Exopharm’s Exoria dye was also identified as the best in-class for labelling exosomes.

The manufacture of clinical-grade exosomes in large-scale requires a Master Cell Bank (MCB) of cells that are securely stored in large numbers and compliant with strict quality requirements.

In early March, the Exopharm’s MCB team reached an important milestone in the establishment of a Current Good Manufacturing Practice (cGMP) Master Cell Bank, successfully developing and validating a HEK293 cell culture to research standards for a second time.

The company says that owning and developing its own exosome medicine products is a priority.

Adveritas (ASX:AV1)

AV1’s Q3 revenue was up 120% on pcp to $473k, with cash receipts growing by 76% to $481k.

The company continues to sign leading enterprises, with names such as William Hill, MyRepublic, Content Fly, MoneySmart, Pomelo Fashion and Superbet.

TrafficGuard’s Google Cloud relationship progressed strongly over the quarter, reflected in the launch of the Google Cloud Marketplace go to market strategy.

The launch took place in April, with dedicated briefings to the Google Cloud Enterprise Account Managers across APAC. These briefings are now yielding introductions from Google into key enterprise accounts.

The partnership is a significant milestone for Adveritas as demand for Google Cloud services is rapidly growing from businesses that also have large digital advertising spends through the Google paid ads channel.

Over the quarter, freemium subscribers increased another 7% from the last quarter to around 4,049 clients. Adveritas believes that freemium subscribers are a key indicator of future revenue growth.

After quarter-end, Adveritas raised $3 million through the issue of convertible notes to strategic, professional and sophisticated investors. The offer was supported by long-term major shareholders, who have participated in previous capital raisings, and new investors.

PharmAust (ASX:PAA)

During. the quarter, PharmAust completed the manufacture of GMP-Grade Monepantel (MPL) for human clinical trials.

The company is currently undergoing a Phase I/II trial examining the effects of MPL in Motor Neurone Disease (MND), otherwise known as Lou Gehrig’s disease or Amyotrophic Lateral Sclerosis (ALS) after receiving a funding commitment of A$881,085.

PharmAust also continues to take key steps towards progressing the evaluation of MPL in human cancers. Clinical interest has so far focused on leukaemia, glioblastoma, esophageal, gastrointestinal, ovarian and pancreatic cancers.

The company is also investigating the use of MPL in patients with COVID-19.

Three laboratories have demonstrated that both MPL and MPLS protect against cell death in vitro following infection with SARS-CoV2.

PharmAust also executed a Research Services Agreement with the Walter and Eliza Hall Institute (WEHI) in Melbourne to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro.

During the quarter, WEHI demonstrated that MPL and MPLS can kill HTLV-1-transformed leukaemia cell lines and inhibit HTLV-1 protein production, as measured by in vitro assays.

PharmAust has made significant progress in canine clinical trials of MPL. Of the seven pet dogs treated with drug plasma levels of MPL in the optimum range, six achieved stable disease of target lesions and one had a partial response (60% regression), with some tumours completely disappearing.

Plans are now to continue and expand the current trial in Australia, New Zealand and the USA for registration of MPL as an anticancer drug in canines with B-cell lymphoma.